^
    Back
    Association details:
    Biomarker:FLT3-ITD mutation + NPM1 mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:Rydapt (midostaurin) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    EHA 2023
    Title:

    NEXT-GENERATION SEQUENCING-BASED MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION TREATED WITH INTENSIVE CHEMOTHERAPY PLUS MIDOSTAURIN

    Published date:
    05/11/2023
    Excerpt:
    To evaluate the prognostic impact of the MRD status in pts 18-70 years with FLT3-ITD+ AML enrolled on the AMLSG16-10 trial (NCT01477606) combining intensive chemotherapy with midostaurin...Concurrent NPM1mut correlated with deeper molecular responses and higher rates of MRD-.
    Secondary therapy:
    Chemotherapy
    Trial ID:
    AMLSG16-10
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Blood Cancer J
    Title:

    Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort

    Published date:
    05/05/2023
    Excerpt:
    We analyzed the impact of midostaurin in 227 FLT3mut-AML patients included in the AML-12 prospective trial for fit patients ≤70 years (#NCT04687098)….The effect of midostaurin was evident in NPM1mut patients (n = 151), with 2-yr OS of 72% (exposed) vs 50% (naive) patients (p = 0.011)....In conclusion, this study highlights the improved outcome of FLT3mut AML fit patients with the incorporation of midostaurin.
    DOI:
    10.1038/s41408-023-00839-1